…and most Enterobacterales, with good CNS penetration — making this the standard choice for community-acquired bacterial meningitis and severe sepsis of unknown origin. The price…

…AV-node slowing. Rate control fails under adrenergic stress — making it a poor choice for the active patient and a reasonable one for the bedridden.

…making it both therapeutic for reentry involving the node and diagnostic for arrhythmias that do not — atrial flutter and atrial tachycardia are unmasked when the…

…hydrocortisone and mineralocorticoid effect is absent, making it suitable in cerebral oedema and cord compression where sodium retention is undesirable. The effect is not immediate…

…no AV block, and no clinically significant negative inotropy, making it combinable with beta-blockers. The price of pure vasodilatation is dependent oedema, which is…

…Absorption is destroyed by food, making the timing of administration a genuine treatment variable and not a formality. The most clinically important adverse effect is…

…making the drug unsuitable as first-line treatment in hypertensive crisis — but useful in pre-eclampsia and as afterload relief in combination with a nitrate…

…infranodal block. The effect comes within one minute and fades over an hour or so, making it a bridge to pacing rather than a treatment.

…with albuminuria, with or without diabetes. The dose is the same — 10 mg once daily — for all indications, making this drug unusually straightforward to manage.

…placebo. IMPROVE-IT showed that the additional LDL lowering also translates into fewer cardiovascular events, making ezetimibe the first non-statin drug with outcome data.

…regimen. Used in peripheral neuropathic pain and as adjunctive treatment in focal epilepsy. Excreted unchanged renally, making renal function the single most important dosing variable.